Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016
03/31/2010

The Benign Prostatic Hyperplasia Therapeutics Market is Forecast to Show Modest Growth Until 2016

Online PR News – 31-March-2010 – – GlobalData’s analysis suggests that the global benign prostatic hyperplasia (BPH) market was worth $3,798m in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 4.5% for the next seven years to reach $5,166m by 2016. This growth rate is primarily attributable to the strong current treatment options as well as a strong pipeline rich in first-in-class molecules. This growth will be further supported by the high incidence rate of the disease and the introduction of first-in-class and me-too therapies with improved clinical benefits.

For more information, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Benign-Prostatic-Hyperplasia-BPH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData analyzed the current competitive landscape for BPH market and found the competition to be strong. There are more than five marketed products for the treatment of BPH, which include finasteride, dutasteride, tamsulosin, doxazosin, alfuzosin, terazosin and silodosin. Competition in the BPH market is driven not only by product characteristics such as their efficacy and safety profile, but also by market characteristics such as the number of competitors, pricing and the introduction of generics.
The BPH market has witnessed a number of patent expiries of major marketed products such as finasteride (Proscar), tamsulosin (Flomax, Harnal) and dutasteride (Avodart) in the US. These major products are likely to be substituted by lower priced generics in the near future. The substitution of these products with cheaper generics will trigger a price war scenario and competition in the BPH market will intensify in the future.
Recently, Duodart, a fixed dose combination of dutasteride and tamsulosin, has received marketing authorization application (MAA) approval in Europe and new drug application (NDA) approval the US. The drug has an improved efficacy and safety profile over the currently marketed products. This implies that Duodart will provide strong competition for the currently marketed products. The competition in the BPH market will further intensify with the launch of strong pipeline candidates which have improved therapeutic outcomes.

For more information, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Benign-Prostatic-Hyperplasia-BPH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData analyzed the BPH pipeline and found it to be strong. The pipeline for BPH consists of more than 15 molecules currently in different stages of development. More than 75% of the BPH pipeline is accounted for by first-in-class molecules. Most of these molecules hold promise with a novel mechanism of action while having an improved efficacy and safety profile. Among the first-in-class molecules, two are in their late stage of development (Phase III) and most of them are in the Phase II clinical stage. Although the BPH pipeline does not have as many me-too molecules, Cialis is one of the most promising molecules in this class which is being studied in Phase III, and it is expected to be launched in the near future. A strong clinical pipeline coupled with moderate unmet need in the BPH market is expected to help sustain the market’s growth rate during the forecast period.

GlobalData, the industry analysis specialist’s new report, “Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global benign prostatic hyperplasia market. The report identifies the key trends shaping and driving the global benign prostatic hyperplasia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global benign prostatic hyperplasia sector.

For more information, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Benign-Prostatic-Hyperplasia-BPH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

Or visit our report store: http://www.globaldata.com/reportstore